Automate Your Wheel Strategy on ZTS
With Tiblio's Option Bot, you can configure your own wheel strategy including ZTS - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol ZTS
- Rev/Share 21.217
- Book/Share 12.1879
- PB 9.8286
- Debt/Equity 0.0378
- CurrentRatio 3.6431
- ROIC 0.2108
- MktCap 52790614470.0
- FreeCF/Share 5.0576
- PFCF 23.5672
- PE 20.0132
- Debt/Assets 0.0135
- DivYield 0.0167
- ROE 0.5356
- Rating A-
- Score 4
- Recommendation Buy
- P/E Score 2
- DCF Score 4
- P/B Score 1
- D/E Score 3
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Downgrade | ZTS | Leerink Partners | Outperform | Market Perform | -- | $155 | July 17, 2025 |
| Downgrade | ZTS | Stifel | Buy | Hold | -- | $160 | June 18, 2025 |
News
Zoetis: Why I'm Still Holding The Stock But Advise Against New Positions
Published: November 07, 2025 by: Seeking Alpha
Sentiment: Negative
Zoetis faces ongoing headwinds as Librela sales disappoint, triggering a sharp post-earnings sell-off and continued stock weakness. Librela's decline, fueled by social media concerns about side effects, overshadows growth in other segments and forces lowered revenue guidance. ZTS trades at a historically low P/E of 20, with a strong product portfolio and robust pipeline, but lacks a clear near-term catalyst for recovery.
Read More
Zoetis Remains A Strong Buy Following Market Overreaction To Q3 Earnings
Published: November 06, 2025 by: Seeking Alpha
Sentiment: Positive
Zoetis Inc. is trading at historically low valuations despite continued EPS and margin growth, following a sharp post-earnings selloff. ZTS's Q3 results showed resilient profitability, but weaker guidance and slowing revenue growth triggered a market rerating from high to low growth. The company maintains strong free cash flow, robust margins, and a leading product pipeline, with new treatments and international expansion supporting long-term growth.
Read More
ZTS Q3 Earnings Beat, Revenues Miss, '25 Sales View Cut, Stock Down
Published: November 04, 2025 by: Zacks Investment Research
Sentiment: Negative
Zoetis tops Q3 earnings forecasts but misses on revenues and trims 2025 sales outlook, sending shares lower on weak U.S. results.
Read More
Zoetis: No Longer A Growth Stock
Published: November 04, 2025 by: Seeking Alpha
Sentiment: Neutral
Zoetis shares have underperformed, falling over 25% in the past year, with recent guidance disappointing investors. Organic growth is slowing, especially in the United States, as core products reach market saturation and macro headwinds weigh on pet care spending. ZTS's valuation has compressed, now trading at a discount to the S&P, reflecting reduced growth expectations and limited near-term catalysts.
Read More
Compared to Estimates, Zoetis (ZTS) Q3 Earnings: A Look at Key Metrics
Published: November 04, 2025 by: Zacks Investment Research
Sentiment: Positive
The headline numbers for Zoetis (ZTS) give insight into how the company performed in the quarter ended September 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Read More
Zoetis: High-Quality Compounder For Patient Long-Term Dividend Growth Investors
Published: November 03, 2025 by: Seeking Alpha
Sentiment: Positive
Zoetis is a US-based company involved in the discovery, development, manufacture, and marketing of animal medicines and vaccines. ZTS has increased its dividend for 13 consecutive years. This streak is as long as it possibly could be, dating back to the company's 2013 IPO. ZTS has a solid financial position. The long-term debt/equity ratio is 1.1, while the interest coverage ratio is right about 15.
Read More
Buy Zoetis Stock Today?
Published: October 31, 2025 by: Forbes
Sentiment: Positive
Zoetis (ZTS) stock warrants your attention. Why? Because it offers high margins – indicative of pricing power and the ability to generate cash – at a discounted price.
Read More
Seeking Clues to Zoetis (ZTS) Q3 Earnings? A Peek Into Wall Street Projections for Key Metrics
Published: October 30, 2025 by: Zacks Investment Research
Sentiment: Positive
Besides Wall Street's top-and-bottom-line estimates for Zoetis (ZTS), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended September 2025.
Read More
Zoetis Gears Up to Report Q3 Earnings: Here's What to Expect
Published: October 29, 2025 by: Zacks Investment Research
Sentiment: Positive
ZTS is poised for another earnings beat as rising demand for companion animal products like Simparica Trio and Apoquel drives expected Q3 revenue growth.
Read More
GRFS vs. ZTS: Which Stock Is the Better Value Option?
Published: October 27, 2025 by: Zacks Investment Research
Sentiment: Neutral
Investors looking for stocks in the Medical - Drugs sector might want to consider either Grifols (GRFS) or Zoetis (ZTS). But which of these two stocks offers value investors a better bang for their buck right now?
Read More
Why Zoetis (ZTS) is Poised to Beat Earnings Estimates Again
Published: October 14, 2025 by: Zacks Investment Research
Sentiment: Positive
Zoetis (ZTS) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Read More
Zoetis Gains CVMP Backing for Lenivia, Eyes EU Approval in Dog OA Pain
Published: October 13, 2025 by: Zacks Investment Research
Sentiment: Positive
ZTS secures CVMP's positive opinion recommending the approval of Lenivia, a long-acting OA pain therapy for dogs, with the final decision expected in late 2025.
Read More
Zoetis: A Solid Investment in the Growing Pet Medicine Market?
Published: October 02, 2025 by: The Motley Fool
Sentiment: Positive
Explore the exciting world of Zoetis (ZTS -0.31%) with our contributing expert analysts in this Motley Fool Scoreboard episode. Check out the video below to gain valuable insights into market trends and potential investment opportunities!
Read More
SDZNY or ZTS: Which Is the Better Value Stock Right Now?
Published: September 29, 2025 by: Zacks Investment Research
Sentiment: Positive
Investors interested in stocks from the Medical - Drugs sector have probably already heard of Sandoz Group AG Sponsored ADR (SDZNY) and Zoetis (ZTS). But which of these two stocks is more attractive to value investors?
Read More
Pet Pain For Investor Gain
Published: September 26, 2025 by: Seeking Alpha
Sentiment: Positive
ZTS is fundamentally a companion animal company, with the segment driving 68% of 2024 revenue and projected to reach 71% by 2030, fueled by aging pet demographics in the US. OA pain franchise, Librela and Solensia, offers differentiated monthly biologic solutions for chronic pain in dogs and cats, but adoption momentum has been dampened by safety concerns. A sum-of-the-parts DCF suggests current share price implies a base-case growth scenario.
Read More
Zoetis Gains CVMP Backing for Portela, Eyes EU Approval in Cat OA Pain
Published: September 15, 2025 by: Zacks Investment Research
Sentiment: Positive
ZTS secures CVMP's positive opinion recommending the approval of Portela, a long-acting OA pain therapy for cats, with final decision expected in late 2025.
Read More
SDZNY vs. ZTS: Which Stock Is the Better Value Option?
Published: September 12, 2025 by: Zacks Investment Research
Sentiment: Neutral
Investors looking for stocks in the Medical - Drugs sector might want to consider either Sandoz Group AG Sponsored ADR (SDZNY) or Zoetis (ZTS). But which of these two stocks is more attractive to value investors?
Read More
SDZNY or ZTS: Which Is the Better Value Stock Right Now?
Published: August 27, 2025 by: Zacks Investment Research
Sentiment: Positive
Investors looking for stocks in the Medical - Drugs sector might want to consider either Sandoz Group AG Sponsored ADR (SDZNY) or Zoetis (ZTS). But which of these two companies is the best option for those looking for undervalued stocks?
Read More
Zoetis to Participate in the Morgan Stanley 23rd Annual Global Healthcare Conference
Published: August 27, 2025 by: Business Wire
Sentiment: Neutral
PARSIPPANY, N.J.--(BUSINESS WIRE)---- $ZTS #animalhealth--Zoetis Inc. (NYSE:ZTS) today announced that a representative from the company will participate in the Morgan Stanley 23rd Annual Global Healthcare Conference on Monday, September 8 at 1:05 p.m. ET. Investors and other interested parties can access a live audio webcast of the presentation by visiting http://investor.zoetis.com/events-presentations. A replay will also be available on the Zoetis website at the conclusion of the event. About Zoetis As the world's.
Read More
SDZNY vs. ZTS: Which Stock Is the Better Value Option?
Published: August 11, 2025 by: Zacks Investment Research
Sentiment: Positive
Investors with an interest in Medical - Drugs stocks have likely encountered both Sandoz Group AG Sponsored ADR (SDZNY) and Zoetis (ZTS). But which of these two companies is the best option for those looking for undervalued stocks?
Read More
2 Stocks to Buy With $5,000 and Hold for a Decade
Published: August 10, 2025 by: The Motley Fool
Sentiment: Positive
It can be tempting to try to predict market movements so you buy low and sell high, but it's notoriously difficult to execute successfully. Even if you succeed once or twice, replicating that often enough to build a profitable portfolio that stands the test of time is next to impossible.
Read More
Top 50 High-Quality Dividend Stocks For August 2025
Published: August 06, 2025 by: Seeking Alpha
Sentiment: Positive
My investable universe of 50 high-quality dividend growth stocks aims to identify attractive opportunities based on valuation and future return potential. Currently, 20 stocks offer an estimated future return of at least 10%, with 10 of these also appearing potentially undervalued by my Free Cash Flow model. Top highlighted stocks like MKTX, RACE, RMD, MSCI, and TTC combine strong free cash flow growth, attractive valuations, and double-digit return estimates.
Read More
Why Zoetis (ZTS) is a Top Growth Stock for the Long-Term
Published: August 06, 2025 by: Zacks Investment Research
Sentiment: Positive
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Read More
ZTS Q2 Earnings & Revenues Beat Estimates, '25 Outlook Raised
Published: August 05, 2025 by: Zacks Investment Research
Sentiment: Positive
Zoetis posts better-than-expected Q2 results with rising sales of pet medicines, boosting its 2025 outlook.
Read More
Zoetis Inc. (ZTS) Q2 2025 Earnings Call Transcript
Published: August 05, 2025 by: Seeking Alpha
Sentiment: Neutral
Zoetis Inc. (NYSE:ZTS ) Q2 2025 Earnings Conference Call August 5, 2025 8:30 AM ET Company Participants Kristin C. Peck - CEO & Director Steven Frank - Vice President of Investor Relations Wetteny N.
Read More
Zoetis (ZTS) Q2 Earnings: How Key Metrics Compare to Wall Street Estimates
Published: August 05, 2025 by: Zacks Investment Research
Sentiment: Positive
The headline numbers for Zoetis (ZTS) give insight into how the company performed in the quarter ended June 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Read More
Zoetis Gears Up to Report Q2 Earnings: Here's What to Expect
Published: August 01, 2025 by: Zacks Investment Research
Sentiment: Positive
ZTS eyes an earnings beat as companion animal drugs like Simparica Trio and Apoquel are expected to drive Q2 revenue gains.
Read More
Countdown to Zoetis (ZTS) Q2 Earnings: A Look at Estimates Beyond Revenue and EPS
Published: July 31, 2025 by: Zacks Investment Research
Sentiment: Positive
Besides Wall Street's top-and-bottom-line estimates for Zoetis (ZTS), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended June 2025.
Read More
USNA or ZTS: Which Is the Better Value Stock Right Now?
Published: July 24, 2025 by: Zacks Investment Research
Sentiment: Positive
Investors with an interest in Medical - Drugs stocks have likely encountered both USANA Health Sciences (USNA) and Zoetis (ZTS). But which of these two stocks presents investors with the better value opportunity right now?
Read More
Why Zoetis (ZTS) Could Beat Earnings Estimates Again
Published: July 18, 2025 by: Zacks Investment Research
Sentiment: Positive
Zoetis (ZTS) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Read More
About Zoetis Inc. (ZTS)
- IPO Date 2013-02-01
- Website https://www.zoetis.com
- Industry Drug Manufacturers - Specialty & Generic
- CEO Kristin C. Peck
- Employees 13800